ArticleClinical and translational medicine2026
Precision medicine for atherosclerotic cardiovascular disease: Integrative genomics maps risk loci and AI-predicted functional consequences.
Article in Clinical and translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAtherosclerotic cardiovascular disease (ASCVD) is a leading cause of global morbidity and mortality, but its genetic architecture remains incompletely understood. This study aims to uncover novel genetic insights into ASCVD through multivariate genomic analysis and molecular structure predictions.
methodsWe analysed genomic data from over 3.8 million individuals across various ASCVD phenotypes, including coronary heart disease, stroke, transient ischemic attack, peripheral artery disease and abdominal aortic aneurysm. Advanced tools such as Genomic Structural Equation Modeling, fine-mapping, FUSION, FOCUS and other functional annotation methods were applied to identify causal single nucleotide polymorphisms associated with ASCVD. Protein structural analysis was performed using AlphaFold3, and AI-driven thermodynamic analysis (ThermoMPNN) assessed the stability and functional consequences of mutations.
resultsOur analysis revealed 347 genome-wide significant variants linked to ASCVD, distributed across 213 loci. Ninety of these variants were not identified in any of the five input GWAS datasets. Upon cross‑referencing with large‑scale external GWAS, 19 of the 90 variants showed no prior association with any cardiovascular or metabolic trait, 15 were previously reported only in risk factor GWAS, and 56 had been reported in direct ASCVD endpoint GWAS. The latter group includes the DCLRE1B rs11552449 missense mutation. Nevertheless, AI‑based structural and thermodynamic analyses revealed that this mutation (H61Y) disrupts DCLRE1B protein stability, increases conformational flexibility, and alters solvent‑accessible surface area-mechanistic insights that have not been previously described.
conclusionsThis study provides a hypothesis‑generating genetic landscape of ASCVD, unveiling novel variants and their molecular impacts. These findings enhance our understanding of ASCVD mechanisms and may offer potential avenues pending experimental validation and targeted therapies in cardiovascular disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.